CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 508 enrolled
Drug / intervention
adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01635764
NCT01635764Phase 3Completed
CompareCT.gov

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

AbbVie (prior sponsor, Abbott)·interventional·Posted Jul 10, 2012·Updated Jan 24, 2018

In Brief

A Phase 3 clinical trial evaluating adalimumab for Hidradenitis Suppurativa. Completed, enrolled 508 participants.

Detailed Summary

The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 10, 2012
Enrollment StartApr 1, 2012
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.0 years ago

Interventions

adalimumabbiological

Adalimumab pre-filled syringe, administered by subcutaneous injection